This randomized, controlled pragmatic trial (n=70) assesses the value of adding edupression.com® as a therapy adjunct to esketamine nasal spray in therapy-resistant depressive (TRD) patients.
Pragmatic randomised parallel-group trial (n=70) comparing treatment-as-usual with esketamine nasal spray plus access to edupression.com® versus esketamine alone in patients with therapy-resistant depression.
Edupression.com® is a licensed, CBT-based digital self-help program (psychoeducation, CBT elements and mood tracking). The study evaluates whether adding this low-intensity psychosocial intervention to esketamine treatment improves clinical outcomes in TRD.
edupression.com® plus treatment-as-usual esketamine nasal spray
edupression.com® digital CBT-based self-help program; full access during study
Esketamine nasal spray (Spravato®) as treatment-as-usual; dose per local label and clinical care
Treatment-as-usual with esketamine nasal spray
Esketamine nasal spray (Spravato®) as treatment-as-usual